mUlticenter, Single-arM, Open-laBel, Long-teRm Safety Study With macitEntan in Patients With puLmonary Arterial Hypertension previousLy Treated With mAcitentan in Clinical Studies (UMBRELLA)
Phase of Trial: Phase III
Latest Information Update: 13 Feb 2019
At a glance
- Drugs Macitentan (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Registrational
- Acronyms UMBRELLA
- Sponsors Actelion Pharmaceuticals
- 09 Apr 2018 Status changed from not yet recruiting to recruiting.
- 28 Mar 2018 Planned End Date changed from 13 Apr 2021 to 2 May 2021.
- 28 Mar 2018 Planned primary completion date changed from 14 Mar 2021 to 3 Apr 2021.